Nothing said here yet.
to join the conversation.
Company plans to explore botanical approval pathways before initiating a prescription drug development programWASHINGTON, Oct.
All five completed patients (100%) reported much or very much improved clinical outcomes and tested negative for Babesia on conventional PCR testsFour of five completed patients (80%) were negative on highly sensitive post-treatment NAT testingResults…
60 Degrees Pharmaceuticals plans to report results from its hospitalized severe babesiosis study in January 2027 and seek FDA feedback that month on a potential supplemental New Drug Application pathway for tafenoquine.
After a scheduled interim analysis of the severe babesiosis study on October 1, 2026, the DSMB recommended completing the study with the originally planned number of patients (N=33); the study remains blindedAs of the same date, the Company had enrolled 30…
ORLANDO, FL / ACCESS Newswire / October 2, 2026 / RedChip Companies will air interviews with 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP; SXTPW) and Exyn Technologies Inc.
Interim analysis results from clinical study evaluating tafenoquine in severe babesiosis (NCT06207370) to be disclosed on October 6, 2026.Key Opinion Leader investor webinar scheduled for October 6, 2026, featuring leading babesiosis experts Dr. Peter Krause and Dr. Edouard Vannier.
WASHINGTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc.
WASHINGTON, July 30, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc.
Company plans to request an FDA meeting following the interim readout to discuss the regulatory pathway for a New Drug Application (NDA) for tafenoquine in babesiosis WASHINGTON, July 29, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc.
License expands collaboration with Florida State University to evaluate castanospermine for Powassan virus disease, tick-borne encephalitis, alpha-gal syndrome, and post-treatment Lyme diseaseAgreement builds on Company's expertise in vector-borne diseases…